Back to News
Market Impact: 0.25

IWM ETF Factor Report

IWMNDAQ
Company FundamentalsAnalyst InsightsHealthcare & Biotech
IWM        ETF Factor Report

Validea's fundamental report on the iShares Russell 2000 ETF (IWM), a Small-Cap Value ETF, reveals its primary tilt towards the value factor with a score of 63, while exhibiting very low scores for quality (13), low volatility (14), and momentum (31). The ETF's portfolio is heavily concentrated in the Services sector and the Biotechnology & Drugs industry, providing institutional investors with a clear understanding of its underlying factor exposures and sector concentrations.

Analysis

Validea's fundamental report on the iShares Russell 2000 ETF (IWM) provides a clear factor-based profile, identifying it as a Small-Cap Value ETF with a specific risk-return signature. The ETF demonstrates a moderately strong tilt towards the value factor, registering a score of 63 out of 99. However, this value orientation is not complemented by other defensive or trend-following characteristics; the fund scores very poorly on Quality (13), Low Volatility (14), and Momentum (31). This factor profile indicates that IWM's holdings are, on average, inexpensive relative to their fundamentals but lack strong balance sheets, stable earnings, or positive price trends. Furthermore, the portfolio's largest industry concentration in Biotechnology & Drugs, a sector known for high volatility and binary outcomes, combined with the low quality and low volatility scores, underscores a significant risk exposure for investors.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

IWM0.00
NDAQ0.00

Key Decisions for Investors

  • Investors seeking dedicated exposure to the small-cap value factor can utilize IWM, but must remain cognizant of its significant weakness in quality and low-volatility characteristics.
  • Given the very low Quality score of 13 and a heavy concentration in the volatile Biotechnology & Drugs industry, this ETF is unsuitable as a core defensive holding and carries a distinctively high-risk profile.
  • The fund's weak Momentum score of 31 suggests it is an inappropriate vehicle for trend-following strategies and may underperform during market rallies driven by momentum stocks.
  • Portfolio managers should consider IWM as a tactical instrument to express a specific view on small-cap value, rather than a diversified proxy for the entire small-cap market.